Status:

TERMINATED

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Lead Sponsor:

Columbia University

Conditions:

Breast Cancer

Colon Cancer

Eligibility:

All Genders

21+ years

Phase:

PHASE2

Brief Summary

Primary Objective: To assess whether six-week treatment with twice daily topical Menthol application will decrease neuropathic pain as measured by the change in Brief Pain Inventory-Short Form (BPI-SF...

Detailed Description

Chemotherapy induced peripheral neuropathy (CIPN): CIPN is a debilitating and often irreversible toxicity associated with various chemotherapy agents widely used in the treatment of both solid tumors ...

Eligibility Criteria

Inclusion

  • Age≥21 years
  • History of stage I-III breast, gastrointestinal or gynecologic cancer
  • Must have received at least one taxane or platinum based chemotherapy drug within two years prior to enrollment.
  • Must exhibit a typical symptom of CIPN that was not present prior to chemotherapy. Symptoms include numbness, tingling, thermal hyperalgesia, cold allodynia in the hands and/or feet, muscle weakness or unsteady gait in at least two of the last seven days prior to registration.
  • Signed informed consent
  • Concomitant biologic, hormonal, or radiation therapy are acceptable
  • Narcotics, antidepressants or other medications for the treatment of CIPN are permitted, if patient on a stable dose for at least one month prior to enrollment

Exclusion

  • Previous treatment with topical menthol (menthol/methylsalicylate products like BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 3 months
  • Known diabetic neuropathy
  • Severe concomitant illnesses
  • Known allergy or preexisting skin disease which prohibits use of menthol
  • Any topical treatment for neuropathy or other serious skin condition on the hands or feet.

Key Trial Info

Start Date :

August 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2016

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT01855607

Start Date

August 1 2013

End Date

November 1 2016

Last Update

July 11 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Herbert Irving Comprehensive Cancer Center

New York, New York, United States, 10032